CONJUPRI TABLETS 2.5MG [SIN17154P]

Product Info

CONJUPRI TABLETS 2.5MG

[SIN17154P]

4.1 Therapeutic indications

Hypertension

Levamlodipine is indicated for the first-line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. Patients not adequately controlled on a single antihypertensive agent may benefit from the addition of levamlodipine, which has been used in combination with a thiazide diuretic, alpha blockers, beta adrenoceptor blocking agent, or an angiotensin-converting enzyme (ACE) inhibitor.

4.2 Posology and method of administration

The usual initial dose is 2.5 mg levamlodipine once daily, which may be increased to a maximum dose of 5 mg depending on the individual patient’s response.

No dose adjustment of levamlodipine is required upon concomitant administration of thiazide diuretics, beta-blockers, and ACE inhibitors.

Use in the Elderly

Normal dosage regimens are recommended. Amlodipine, used at similar doses in the elderly or younger patients, is equally well-tolerated.

Use in Children

Safety and effectiveness of levamlodipine in children have not been established.

Use in Patients with Impaired Hepatic Function

See section 4.4. Special warnings and precautions for use – please refer to the Product Insert/Patient Information Leaflet published on HSA for the full drug information.

Use in Patients with Renal Failure

Levamlodipine may be used at normal doses in patients with renal failure. Changes in amlodipine plasma concentrations are not correlated with the degree of renal impairment.

Amlodipine is not dialyzable.

4.3 Contraindications

Levamlodipine is contraindicated in patients with a known hypersensitivity to dihydropyridines* or any of the inert ingredients.

* Amlodipine is a dihydropyridine calcium channel blocker.